During the last years, CDK4/6 inhibitors have changed the treatment landscape of hormone receptor‐positive and HER‐2‐negative breast tumors offering large progression‐free intervals to many patients with invasive breast cancer. The gene discussed is ERBB2; the disease is invasive breast carcinoma.